Tirzepatide vs Liraglutide in Bone

This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.

NCT Number	NCT07094568
Lead Sponsor	National and Kapodistrian University of Athens Collaborators: Laikο General Hospital, Athens, Athens Medical Center, Sotiria General Hospital, 251 Hellenic Air Force & VA General Hospital, Evangelismos Hospital
Conditions	Obesity (Disorder)
Enrollment	72 participants
Start Date	2025-05-23
Primary Completion	2026-12-30 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-21